A Phase 2 interventional study of fosmanogepix in Invasive Fungal Infections, sponsored by Basilea Pharmaceutica. Terminated at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Basilea Pharmaceutica · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Invasive Fungal Infections with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Invasive Fungal Infections · United States.
Among the 24 studies in Invasive Fungal Infections with a site in United States, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 19th registered.
136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.
Browse Invasive Fungal Infections studies →2 of the 24 studies in Invasive Fungal Infections with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Belgium, Greece and 7 more countries
Ages 1 days–2 yrs
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1 days–99 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 12 · Phase 4 1
First in 1997; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 70 across 67 interventional studies indexed under Invasive Fungal Infections.
Median enrollment 88 across the 19 interventional studies, 172 across the 5 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 24 have an industry lead sponsor. The 10 most frequent:
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Basilea Pharmaceutica has 3 studies filed under Invasive Fungal Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Invasive Fungal Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04665037Merck Sharp & Dohme LLCPosaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Invasive Fungal Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: fosmanogepix
Drug: fosmanogepix
IV and oral fosmanogepix
Also known as: APX001, E210
Percentage of Participants Who Died After the First Dose of Study Drug Through Day 42
Percentage of participants who died after first dose in the study through Day 42 were reported in this outcome measure. This outcome measure included all deaths from Day 1 through Day 42.
Time frame: After first dose on Day 1 through Day 42
Percentage of Participants With Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)
Global response was classified as treatment success (complete or partial response \[CR or PR\]) or treatment failure (stable response \[SR\], progression of fungal disease \[PD\], or death) as determined by DRC. CR: survival within prespecified period of observation (PPOB), resolution of all attributable (att) symptoms and signs of disease and radiological (rad) abnormalities, and mycological (myco) evidence of eradication of disease. PR: survival within POB, improvement in att symptoms and signs of disease and rad abnormalities, and evidence of clearance of cultures or reduction of fungal burden. SR: survival within PPOB, minor or no improvement in fungal disease but no evidence of progression based on composite of clinical, rad and myco criteria, PD or death. PD: evidence of progressive fungal disease based on composite of clinical, rad and myco criteria. Death: death during PPOB, regardless of attribution. Data is presented for EOST which could have preceded Day 42 for some participants.
Time frame: Any day from Day 1 until end of study treatment (any day up to Day 42)
Percentage of Participants With Treatment Success or Treatment Failure for Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)
Global response was classified as treatment success (CR or PR) or treatment failure (SR, PD or death) as determined by DRC. CR: survival within prespecified POB, resolution of all attributable symptoms and signs of disease and rad abnormalities and myco evidence of eradication of disease. PR: survival within prespecified POB, improvement in attributable symptoms and signs of disease and rad abnormalities and evidence of clearance of cultures or reduction of fungal burden. SR: survival within prespecified POB, minor or no improvement in fungal disease, but no evidence of progression, based on composite of clinical, rad, and myco criteria, PD or death. PD: evidence of PD based on a composite of clinical, rad, and myco criteria. Death: death during prespecified period of evaluation, regardless of attribution. Percentage of participants with treatment success (CR, PR) and treatment failure (SR, PD, death) along with two-sided exact binomial 80% confidence interval is presented.
Time frame: Any day from Day 1 until end of study treatment (any day up to Day 42)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to 4 weeks post last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state. An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. AEs included SAEs and all non-SAEs.
Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Number of Participants With Clinically Significant Abnormality in Vital Signs
Vital signs included body temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation. Number of participants with clinically significant abnormality in vital signs as judged by investigator were reported in this outcome measure.
Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Number of Participants With Clinically Significant Abnormality in Laboratory Test Evaluations
Clinical laboratory assessments included serum chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, creatinine, creatine kinase), hematology (including hemoglobin, hematocrit, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes), coagulation (including Prothrombin time \[PT\]/ International normalized ratio \[INR\]), and urinalysis. Number of participants with clinically significant abnormality in any laboratory parameter as judged by investigator and reported as adverse events were presented.
Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings
ECG parameters included PR interval, QRS interval, QT interval, QT interval corrected using the Fridericia's formula (QTcF), QT interval corrected using the Bazett's formula (QTcB), RR interval and heart rate. Number of participants with clinically significant abnormal ECG findings as judged by investigator were presented.
Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examinations
Physical examination included an assessment of general appearance, skin, eyes, heart, chest, abdomen, and a neurological examination. Components of the neurological examination included cranial nerve, sensory, and motor examination; reflex and gait testing; and coordination assessment. Clinically significant changes were judged by investigator.
Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Plasma Concentrations of Fosmanogepix
Time frame: Days 1, 2, 3, 4, 7: Pre-dose and 3 hours post-dose; Days 6, 13, 14: 3 hours post-dose, Day 15: pre-dose
Study was planned to be conducted in two parallel cohorts: Cohort A included participants with invasive mold infections (IMA) and an exploratory Cohort B was planned to include participants with invasive aspergillus, who had COVID-19 or Influenza A/B. The study was terminated early and no participants were enrolled in Cohort B; hence data is not reported for Cohort B in any section.
| Milestone | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Started | 21 |
| Completed | 11 |
| Not completed | 10 |
| Withdrew: Death | 4 |
| Withdrew: Discontinuation by subject | 1 |
| Withdrew: Adverse event | 5 |
| Milestone | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Started | 17 |
| Completed | 13 |
| Not completed | 4 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Discontinuation by subject | 1 |
| Withdrew: Death | 2 |
Percentage of participants who died after first dose in the study through Day 42 were reported in this outcome measure. This outcome measure included all deaths from Day 1 through Day 42.
| Percentage of participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Percentage of Participants Who Died After the First Dose of Study Drug Through Day 42 | 25.0 (12.7 to 41.5) |
Global response was classified as treatment success (complete or partial response \[CR or PR\]) or treatment failure (stable response \[SR\], progression of fungal disease \[PD\], or death) as determined by DRC. CR: survival within prespecified period of observation (PPOB), resolution of all attributable (att) symptoms and signs of disease and radiological (rad) abnormalities, and mycological (myco) evidence of eradication of disease. PR: survival within POB, improvement in att symptoms and signs of disease and rad abnormalities, and evidence of clearance of cultures or reduction of fungal burden. SR: survival within PPOB, minor or no improvement in fungal disease but no evidence of progression based on composite of clinical, rad and myco criteria, PD or death. PD: evidence of progressive fungal disease based on composite of clinical, rad and myco criteria. Death: death during PPOB, regardless of attribution. Data is presented for EOST which could have preceded Day 42 for some participants.
| Percentage of participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| CR | 20.0 |
| PR | 20.0 |
| SR | 10.0 |
| PD | 30.0 |
| Death | 20.0 |
Global response was classified as treatment success (CR or PR) or treatment failure (SR, PD or death) as determined by DRC. CR: survival within prespecified POB, resolution of all attributable symptoms and signs of disease and rad abnormalities and myco evidence of eradication of disease. PR: survival within prespecified POB, improvement in attributable symptoms and signs of disease and rad abnormalities and evidence of clearance of cultures or reduction of fungal burden. SR: survival within prespecified POB, minor or no improvement in fungal disease, but no evidence of progression, based on composite of clinical, rad, and myco criteria, PD or death. PD: evidence of PD based on a composite of clinical, rad, and myco criteria. Death: death during prespecified period of evaluation, regardless of attribution. Percentage of participants with treatment success (CR, PR) and treatment failure (SR, PD, death) along with two-sided exact binomial 80% confidence interval is presented.
| Percentage of participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Treatment Success | 40.0 (24.9 to 56.7) |
| Treatment Failure | 60.0 (43.3 to 75.1) |
An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to 4 weeks post last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state. An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. AEs included SAEs and all non-SAEs.
| Participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| TEAEs | 21 |
| SAEs | 13 |
Vital signs included body temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation. Number of participants with clinically significant abnormality in vital signs as judged by investigator were reported in this outcome measure.
| Participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Number of Participants With Clinically Significant Abnormality in Vital Signs | 5 |
Clinical laboratory assessments included serum chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, creatinine, creatine kinase), hematology (including hemoglobin, hematocrit, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes), coagulation (including Prothrombin time \[PT\]/ International normalized ratio \[INR\]), and urinalysis. Number of participants with clinically significant abnormality in any laboratory parameter as judged by investigator and reported as adverse events were presented.
| Participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Number of Participants With Clinically Significant Abnormality in Laboratory Test Evaluations | 12 |
ECG parameters included PR interval, QRS interval, QT interval, QT interval corrected using the Fridericia's formula (QTcF), QT interval corrected using the Bazett's formula (QTcB), RR interval and heart rate. Number of participants with clinically significant abnormal ECG findings as judged by investigator were presented.
| Participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings | 0 |
Physical examination included an assessment of general appearance, skin, eyes, heart, chest, abdomen, and a neurological examination. Components of the neurological examination included cranial nerve, sensory, and motor examination; reflex and gait testing; and coordination assessment. Clinically significant changes were judged by investigator.
| Participants | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examinations | 3 |
| nanogram per milliliter | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Day 1: Pre-dose | 0.0 ± 0.0 |
| Day 1: 3 hrs post-dose | 387.4 ± 289.6 |
| Day 2: Pre-dose | 20.4 ± 138.1 |
| Day 2: 3 hrs post-dose | 406.4 ± 202.9 |
| Day 3: Pre-dose | 8.6 ± 184.1 |
| Day 3: 3 hrs post-dose | 486.7 ± 154.6 |
| Day 4: Pre-dose | 2.9 ± 141.3 |
| Day 4: 3 hrs post-dose | 85.2 ± 14743.4 |
| Day 6: 3 hrs post-dose | 6.8 ± 1541.9 |
| Day 7: Pre-dose | 9.8 ± 716.5 |
| Day 7: 3 hrs post-dose | 37.9 ± 382.3 |
| Day 13: 3 hrs post-dose | 96.4 ± NA |
| Day 14: 3 hrs post-dose | 706.8 ± 181.0 |
| Day 15: Pre-dose | 0.5 ± NA |
Collected over For adverse events (SAEs and non-SAEs): Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days); for all-cause mortality: Throughout the study (Day 1 to Day 84). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| APX001 (Fosmanogepix): Cohort A | 9/21 (42.9%) | 13/21 (61.9%) | 21/21 (100%) |
| Event | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/21 |
| Cardiac arrestCardiac disorders | 2/21 |
| DiarrhoeaGastrointestinal disorders | 2/21 |
| SepsisInfections and infestations | 2/21 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/21 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/21 |
| Ventricular tachycardiaCardiac disorders | 1/21 |
| Abdominal painGastrointestinal disorders | 1/21 |
| VomitingGastrointestinal disorders | 1/21 |
| Sudden deathGeneral disorders | 1/21 |
| Event | APX001 (Fosmanogepix): Cohort A |
|---|---|
| NauseaGastrointestinal disorders | 13/21 |
| DiarrhoeaGastrointestinal disorders | 10/21 |
| VomitingGastrointestinal disorders | 9/21 |
| Oedema peripheralGeneral disorders | 6/21 |
| Decreased appetiteMetabolism and nutrition disorders | 6/21 |
| PyrexiaGeneral disorders | 5/21 |
| Abdominal painGastrointestinal disorders | 4/21 |
| ChillsGeneral disorders | 4/21 |
| Aspartate aminotransferase increasedInvestigations | 4/21 |
| HeadacheNervous system disorders | 4/21 |
Safety population included all participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Mean | 62.38 ± 11.71 |
| Sex: Female, Male(Participants) | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Female | 2 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | APX001 (Fosmanogepix): Cohort A |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | APX001 (Fosmanogepix): Cohort A |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Mar 2022, 26 months.
Results were first posted in May 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fosmanogepix